Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Conditions
Brief summary
This phase I/II trial studies the side effects and how well localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy works in treating patients with Merkel cell carcinoma that has spread to other parts of the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Interferon beta is a substance that can improve the body's natural response and may interfere with the growth of tumor cells. Monoclonal antibodies, such as avelumab, may help T lymphocytes kill tumor cells. For cellular adoptive immunotherapy, specific white blood cells are collected from the patient's blood and treated in the laboratory to recognize Merkel cell carcinoma. Infusing these cells back into the patient may help the body build an effective immune response to kill Merkel cell carcinoma. Giving localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy may be a better treatment for Merkel cell carcinoma.
Detailed description
PRIMARY OBJECTIVES: I. Assess and compare the safety and potential toxicities associated with treating patients with metastatic Merkel cell carcinoma (MCC) with either major histocompatibility complex (MHC) up regulation and programmed cell death 1 (PD1)-axis blockade (Group 1), or MHC up-regulation, PD1-axis blockade and adoptive transfer of Merkel cell polyoma virus (MCPyV) T antigen (TAg)-specific polyclonal autologous cluster of differentiation (CD)8+ T cells (Group 2). II. Assess and compare the antitumor efficacy associated with treating patients with metastatic MCC with either MHC up-regulation and PD1-axis blockade (Group 1), or MHC up-regulation, PD1-axis blockade and adoptive transfer of MCPyV TAg-specific polyclonal autologous CD8+ T cells (Group 2). SECONDARY OBJECTIVES: I. Examine the in vivo persistence and, where evaluable, migration to tumor sites of adoptively transferred polyclonal CD8+ T cells targeting the MCPyV TAg (Group 2). II. Examine the in vivo functional capacity of adoptively transferred polyclonal CD8+ T cells targeting the MCPyV Tag (Group 2). III. Examine and compare evidence of epitope spreading with either MHC up-regulation and adoptive transfer of MHC up-regulation and PD1-axis blockade (Group 1), or MHC up regulation, PD1-axis blockade and adoptive transfer of MCPyV TAg-specific polyclonal autologous CD8+ T cells (Group 2). OUTLINE: Patients are assigned to 1 of 2 groups. GROUP 1: Patients who do not have a human leukocyte antigen (HLA) type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection. GROUP 2: Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes. In both groups, MHC class I up-regulation treatment with or without T cell infusions may repeat if indicated. After completion of study treatment, patients are followed up at 12 months and then periodically thereafter.
Interventions
DRUGAvelumab
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
Given IV
RADIATIONRadiation Therapy
Undergo radiation therapy
BIOLOGICALRecombinant Interferon Beta
Given via intra-tumor injection
Sponsors
EMD Serono
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent * Confirmation of MCC by internal pathology review of initial or subsequent biopsy or other pathologic material * If an accessible lesion is present, a biopsy will be performed within 6 weeks of the start of study intervention; the results of the biopsy must be obtained prior to initiation of study intervention * Evidence of MCPyV TAg tumor expression by immunohistochemistry on any prior or current tumor specimen or viral oncoprotein antibody confirmation within 6 weeks of the start of study intervention * Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\< 2 at trial entry * Patients must have at least one bi-dimensionally measurable lesion by palpation, clinical exam, or radiographic imaging within 6 weeks of the start of study intervention (X-ray, computed tomography \[CT\] scan, positron emission tomography \[PET\] scan, magnetic resonance imaging \[MRI\], or ultrasound) * For patients designated to be treated on Group 2: cardiac ejection fraction \>= 35%; for patients with significant risk factors for coronary artery disease (Framingham risk score \> 15%), a cardiac stress test is recommended * At least 3 weeks must have passed since any of the following: systemic corticosteroids, immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, MCC vaccines, intravenous immunoglobulin, expanded polyclonal tumor infiltrating lymphocytes \[TIL\] or lymphokine-activated killer \[LAK\] therapy), pentoxifylline, other small molecule or chemotherapy cancer treatment, other investigational agents or other systemic agents that target Merkel cell carcinoma
Exclusion criteria
* Known active infections or oral temperature \> 38.2 Celsius (C) fewer than 72 hours prior to receiving study treatment or systemic infection requiring chronic maintenance or suppressive therapy * White blood cells (WBC) \< 200/mcl * Hemoglobin (Hb) \< 8 g/dL * Absolute neutrophil count (ANC) \< 1000/mcl * Platelets \< 50,000/mcl * New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, stable or unstable angina, symptoms of coronary artery disease, congestive heart failure, clinically significant hypotension, or history of an ejection fraction of =\< 30 % (echocardiogram or multi gated acquisition scan \[MUGA\]) * Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in 1 second (FEV1) \< 2.0 L or diffusion capacity of the lung for carbon monoxide (DLco) (corrected \[corr\] for hemoglobin \[Hgb\]) \< 50% will be excluded * Creatinine clearance \< 30 ml/min which cannot be attributed to MCC metastasis * Total bilirubin \> 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2.5 x ULN; for patients with liver metastases: AST/ALT \> 5 x ULN * Active autoimmune disease (e.g. systemic lupus erythematosus, vasculitis, infiltrating lung disease, inflammatory bowel disease) whose possible progression during treatment would be considered unacceptable by the investigators * Symptomatic and untreated central nervous system (CNS) metastasis; however, patients with 1 to 2 asymptomatic, less than 1 cm brain/CNS metastases without significant edema may be considered for treatment; if sub-centimeter CNS lesions are noted at study entry, then repeat imaging will be performed, if more than 4 weeks have elapsed from the last scan * Any condition or organ toxicity that is deemed by the principal investigator (PI) or the attending physician to place the patient at unacceptable risk for treatment on the protocol * Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within 2-6 weeks prior to treatment * Clinically significant and ongoing immune suppression including, but not limited to, systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection, or solid organ transplantation * Patients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this study * Known severe hypersensitivity reactions to monoclonal antibodies (grade \>= 3 National Cancer Institute \[NCI\]-Common Terminology Criteria for Adverse Events \[CTCAE\] version \[v\] 4.0), any history of anaphylaxis, or uncontrolled asthma * Vaccination with live inactivated viral strains for the prevention of infectious diseases within 4 weeks of the start of the study treatment, inactivated influenza vaccines are permitted while on trial * Known alcohol or drug abuse * Legal incapacity or limited legal capacity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evidence of Response, Based on Median Time to New Metastasis | Up to 1 year | Median time to new metastases reported for each group below. Group 1 result is NA, patient had no new detectable metastases in study follow-up period. Arm I is not analyzed because the one patient in Arm I did not experience new metastasis in their followup period, so they are not evaluable. |
| Count of Participants Who Experienced Adverse Events, Evaluated According to the Current Guidelines in National Cancer Institute (NCI) Common Toxicity Criteria Version 4.0 | Up to 4 weeks after the last infusion | Evidence and nature of toxicity related to the treatment will be assessed and compared between groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Functional Capacity of Transferred T Cells (Group 2) | Up to 3 months | To evaluate the direct ex vivo function of the transferred cells, where possible, tetramer+ cells within collected peripheral blood mononuclear cells (PBMCs) will be evaluated for production of intracellular cytokines including interferon (IFN), tumor necrosis factor alpha and interleukin-2 in response to cognate antigen using an intracellular cytokine assay. This endpoint was evaluable in 4 of 7 patients, all 4 of whom upregulated interferon, tumor necrosis factor alpha and IL-2 expression in response to cognate antigen using intracellular cytokine assay. Persistence was not detected for 3 out of 7 patients in group 2, making them unevaluable for functional capacity. |
| Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | 28 days post infusion | Patients were evaluated for their disease response throughout their follow up period. Disease response reported is best response per patient. A complete response (CR) will be defined as total regression of all tumors, a PR as 30% or greater decrease in the sum of the longest diameter of target lesions compared to baseline and PD as 20% increase in the sum of the longest diameter of target lesions compared to the smallest prior diameter (RECIST v1.1 criteria). |
| Count of Participants Who Displayed Persistence of Transferred T Cells in Blood and Tumor (Group Co2) | Up to 90 days post infusion | Persistence of trasferred T cells was evaluated and assessed after 90 days. Patients were counted if transferred T cells were detected beyond 90 days. |
| Merkel Cell Carcinoma (MCC)-Specific Survival | Up to 1 year | Survival status in patients with Merkel cell carcinoma will be evaluated. Data is reported as count of participants that survived past the 1 year follow up period. |
| Count of Participants That Displayed Evidence of Epitope Spreading | Up to 3 months | Quantification of the overall recognition of the MCPyV T-antigen for each patient will likely be performed by testing the reactivity of whole peripheral blood mononuclear cells (PBMC) before and at indicated timepoints after treatment to peptides 15 amino acids (aa) in length offset by 5 aa bases spanning the whole T-antigen protein to include both CD8 and CD4 responses regardless of the HLA type of the patient. Due to changes in assay technology, epitope spreading was detected using a flow cytometric based intracellular cytokine assay. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Group 1 (Avelumab and MHC Class I Up-regulation) Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
Avelumab: Given IV
Laboratory Biomarker Analysis: Correlative studies
Radiation Therapy: Undergo radiation therapy
Recombinant Interferon Beta: Given via intra-tumor injection | 1 |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
Avelumab: Given IV
Laboratory Biomarker Analysis: Correlative studies
MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells: Given IV
Radiation Therapy: Undergo radiation therapy
Recombinant Interferon Beta: Given via intra-tumor injection | 7 |
| Total | 8 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Physician Decision | 1 | 0 |
| Overall Study | Progressive Disease | 0 | 3 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | Group 1 (Avelumab and MHC Class I Up-regulation) | Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 7 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 7 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 7 Participants | 8 Participants |
| Region of Enrollment United States | 1 participants | 7 participants | 8 participants |
| Sex: Female, Male Female | 0 Participants | 3 Participants | 3 Participants |
| Sex: Female, Male Male | 1 Participants | 4 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 1 | 3 / 7 |
| other Total, other adverse events | 1 / 1 | 6 / 7 |
| serious Total, serious adverse events | 1 / 1 | 0 / 7 |
Outcome results
Primary
Count of Participants Who Experienced Adverse Events, Evaluated According to the Current Guidelines in National Cancer Institute (NCI) Common Toxicity Criteria Version 4.0
Evidence and nature of toxicity related to the treatment will be assessed and compared between groups.
Time frame: Up to 4 weeks after the last infusion
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Count of Participants Who Experienced Adverse Events, Evaluated According to the Current Guidelines in National Cancer Institute (NCI) Common Toxicity Criteria Version 4.0 | 1 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Count of Participants Who Experienced Adverse Events, Evaluated According to the Current Guidelines in National Cancer Institute (NCI) Common Toxicity Criteria Version 4.0 | 6 Participants |
Primary
Evidence of Response, Based on Median Time to New Metastasis
Median time to new metastases reported for each group below. Group 1 result is NA, patient had no new detectable metastases in study follow-up period. Arm I is not analyzed because the one patient in Arm I did not experience new metastasis in their followup period, so they are not evaluable.
Time frame: Up to 1 year
Population: Patient in group 1 did not experience new metastasis in followup period of 1 year. Only 4 patients in group 2 experienced new metastases in the followup period of 1 year. The other 3 patients in group 2 were omitted due to no new metastases.
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Evidence of Response, Based on Median Time to New Metastasis | 53 Days | Standard Deviation 23.45 |
Secondary
Count of Participants That Displayed Evidence of Epitope Spreading
Quantification of the overall recognition of the MCPyV T-antigen for each patient will likely be performed by testing the reactivity of whole peripheral blood mononuclear cells (PBMC) before and at indicated timepoints after treatment to peptides 15 amino acids (aa) in length offset by 5 aa bases spanning the whole T-antigen protein to include both CD8 and CD4 responses regardless of the HLA type of the patient. Due to changes in assay technology, epitope spreading was detected using a flow cytometric based intracellular cytokine assay.
Time frame: Up to 3 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Count of Participants That Displayed Evidence of Epitope Spreading | 2 Participants |
Secondary
Count of Participants Who Displayed Persistence of Transferred T Cells in Blood and Tumor (Group Co2)
Persistence of trasferred T cells was evaluated and assessed after 90 days. Patients were counted if transferred T cells were detected beyond 90 days.
Time frame: Up to 90 days post infusion
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Count of Participants Who Displayed Persistence of Transferred T Cells in Blood and Tumor (Group Co2) | 4 Participants |
Secondary
Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1
Patients were evaluated for their disease response throughout their follow up period. Disease response reported is best response per patient. A complete response (CR) will be defined as total regression of all tumors, a PR as 30% or greater decrease in the sum of the longest diameter of target lesions compared to baseline and PD as 20% increase in the sum of the longest diameter of target lesions compared to the smallest prior diameter (RECIST v1.1 criteria).
Time frame: 28 days post infusion
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Partial Response | 0 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Progressive Disease | 0 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Stable Disease | 0 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Partial Complete Response | 0 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Complete Response | 1 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Partial Complete Response | 1 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Complete Response | 2 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Partial Response | 1 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Stable Disease | 0 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Disease Response, as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 | Progressive Disease | 3 Participants |
Secondary
Functional Capacity of Transferred T Cells (Group 2)
To evaluate the direct ex vivo function of the transferred cells, where possible, tetramer+ cells within collected peripheral blood mononuclear cells (PBMCs) will be evaluated for production of intracellular cytokines including interferon (IFN), tumor necrosis factor alpha and interleukin-2 in response to cognate antigen using an intracellular cytokine assay. This endpoint was evaluable in 4 of 7 patients, all 4 of whom upregulated interferon, tumor necrosis factor alpha and IL-2 expression in response to cognate antigen using intracellular cytokine assay. Persistence was not detected for 3 out of 7 patients in group 2, making them unevaluable for functional capacity.
Time frame: Up to 3 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Functional Capacity of Transferred T Cells (Group 2) | 4 Participants |
Secondary
Merkel Cell Carcinoma (MCC)-Specific Survival
Survival status in patients with Merkel cell carcinoma will be evaluated. Data is reported as count of participants that survived past the 1 year follow up period.
Time frame: Up to 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Merkel Cell Carcinoma (MCC)-Specific Survival | 1 Participants |
| Group 2 (Avelumab, MHC Class I Up-regulation, T Cells) | Merkel Cell Carcinoma (MCC)-Specific Survival | 6 Participants |